Structural Evaluation of Potent NKT Cell Agonists: Implications for Design of Novel Stimulatory Ligands

Journal of Molecular Biology

Volumn 394, Issue 1, 2009, Pages 71-82

  Schiefner, André ^a   Fujio, Masakazu ^a   Wu, Douglass ^a   Wong, Chi Huey ^a   Wilson, Ian A ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

CD1; glycolipids; immune system; NKT cells; GalCer analogues

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; CD1D ANTIGEN; CYTOKINE; FATTY ACID; GALACTOSE; GLYCOLIPID; LIGAND; SPHINGOSINE; T LYMPHOCYTE RECEPTOR; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN;

ARTICLE; CONFORMATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; CRYSTALLOGRAPHY; CYTOKINE RELEASE; HELPER CELL; MOLECULAR RECOGNITION; MOLECULAR STABILITY; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; ANTIGENS, CD1D; CRYSTALLOGRAPHY, X-RAY; GLYCOLIPIDS; LIGANDS; LYMPHOCYTE ACTIVATION; MICE; MODELS, MOLECULAR; NATURAL KILLER T-CELLS; PLIABILITY; PROTEIN STRUCTURE, SECONDARY; STATIC ELECTRICITY;

EID: 70350135734     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2009.08.061     Document Type: Article

References (36)

1. Barral D.C., and Brenner M.B. CD1 antigen presentation: how it works. Nat. Rev., Immunol. 7 (2007) 929-941
2. Godfrey D.I., and Kronenberg M. Going both ways: immune regulation via CD1d-dependent NKT cells. J. Clin. Invest. 114 (2004) 1379-1388
3. Bendelac A., Savage P.B., and Teyton L. The biology of NKT cells. Annu. Rev. Immunol. 25 (2007) 297-336
4. Kawano T., Cui J., Koezuka Y., Toura I., Kaneko Y., Motoki K., et al. CD1d-restricted and TCR-mediated activation of Vα14 NKT cells by glycosylceramides. Science 278 (1997) 1626-1629
5. Berkers C.R., and Ovaa H. Immunotherapeutic potential for ceramide-based activators of iNKT cells. Trends Pharmacol. Sci. 26 (2005) 252-257
6. Van Kaer L. α-Galactosylceramide therapy for autoimmune diseases: prospects and obstacles. Nat. Rev., Immunol. 5 (2005) 31-42
7. Kronenberg M. Toward an understanding of NKT cell biology: progress and paradoxes. Annu. Rev. Immunol. 23 (2005) 877-900
8. Koch M., Stronge V.S., Shepherd D., Gadola S.D., Mathew B., Ritter G., et al. The crystal structure of human CD1d with and without α-galactosylceramide. Nat. Immunol. 6 (2005) 819-826
9. Zajonc D.M., Cantu C., Mattner J., Zhou D., Savage P.B., Bendelac A., et al. Structure and function of a potent agonist for the semi-invariant natural killer T cell receptor. Nat. Immunol. 6 (2005) 810-818
10. Zeng Z.-H., Castano A.R., Segelke B.W., Stura E.A., Peterson P.A., and Wilson I.A. Crystal structure of mouse CD1: an MHC-like fold with a large hydrophobic binding groove. Science 277 (1997) 339-345
11. Zajonc D.M., Maricic I., Wu D., Halder R., Roy K., Wong C.-H., et al. Structural basis for CD1d presentation of sulfatide derived myelin and its implications for autoimmunity. J. Exp. Med. 202 (2005) 1517-1526
12. Wu D., Zajonc D.M., Fujio M., Sullivan B.A., Kinjo Y., Kronenberg M., et al. Design of natural killer T cell activators: structure and function of a microbial glycosphingolipid bound to mouse CD1d. Proc. Natl. Acad. Sci. USA 103 (2006) 3972-3977
13. Zajonc D.M., Savage P.B., Bendelac A., Wilson I.A., and Teyton L. Crystal structures of mouse CD1d-iGb3 complex and its cognate Vα14 T cell receptor suggest a model for dual recognition of foreign and self glycolipids. J. Mol. Biol. 377 (2008) 1104-1116
14. Borg N.A., Wun K.S., Kjer-Nielsen L., Wilce M.C.J., Pellicci D.G., Koh R., et al. CD1d-lipid-antigen recognition by the semi-invariant NKT T-cell receptor. Nature 448 (2007) 44-49
15. Goff R.D., Gao Y., Mattner J., Zhou D., Yin N., Cantu III C., et al. Effects of lipid chain lengths in α-galactosylceramides on cytokine release by natural killer T cells. J. Am. Chem. Soc. 126 (2004) 13602-13603
16. Chen G., Chien M., Tsuji M., and Franck R.W. E and Z α-C-galactosylceramides by Julia-Lythgoe-Kocienski chemistry: a test of the receptor-binding model for glycolipid immunostimulants. ChemBioChem 7 (2006) 1017-1022
17. Silk J.D., Salio M., Reddy B.G., Shepherd D., Gileadi U., Brown J., et al. Cutting edge: nonglycosidic CD1d lipid ligands activate human and murine invariant NKT cells. J. Immunol. 180 (2008) 6452-6456
18. Fujio M., Wu D., Garcia-Navarro R., Ho D.D., Tsuji M., and Wong C.-H. Structure-based discovery of glycolipids for CD1d-mediated NKT cell activation: tuning the adjuvant versus immunosuppression activity. J. Am. Chem. Soc. 128 (2006) 9022-9023
19. Liang P.-H., Imamura M., Li X., Wu D., Fujio M., Guy R.T., et al. Quantitative microarray analysis of intact glycolipid-CD1d interaction and correlation with cell-based cytokine production. J. Am. Chem. Soc. 130 (2008) 12348-12354
20. Ding Y.H., Baker B.M., Garboczi D.N., Biddison W.E., and Wiley D.C. Four A6-TCR/peptide/HLA-A2 structures that generate very different T cell signals are nearly identical. Immunity 11 (1999) 45-56
21. Baker B.M., Gagnon S.J., Biddison W.E., and Wiley D.C. Conservation of a T cell antagonist into an agonist by repairing a defect in the TCR/peptide/MHC interface: implications for TCR signaling. Immunity 13 (2000) 457-484
22. Wun K.S., Borg N.A., Kjer-Nielsen L., Beddoe T., Koh R., Richardson S.K., et al. A minimal binding footprint on CD1d-glycolipid is a basis for selection of the unique human NKT TCR. J. Exp. Med. 205 (2008) 939-949
23. Scott-Browne J.P., Matsuda J.L., Mallevaey T., White J., Borg N.A., McCluskey J., et al. Germline-encoded recognition of diverse glycolipids by natural killer T cells. Nat. Immunol. 8 (2007) 1105-1113
24. Wang Z., Canagarajah B.J., Boehm J.C., Kassisa S., Cobb M.H., Young P.R., et al. Structural basis of inhibitor selectivity in MAP kinases. Structure 6 (1998) 1117-1128
25. Müller K., Faeh C., and Diederich F. Fluorine in pharmaceuticals: looking beyond intuition. Science 317 (2007) 1881-1886
26. McCarthy C., Shepherd D., Fleire S., Stronge V.S., Koch M., Illarionov P.A., et al. The length of lipids bound to human CD1d molecules modulates the affinity of NKT cell TCR and the threshold of NKT cell activation. J. Exp. Med. 204 (2007) 1131-1144
27. Im J.S., Arora P., Bricard G., Molano A., Venkataswamy M.M., Baine I., et al. Kinetics and cellular site of glycolipid loading control the outcome of natural killer T cell activation. Immunity 30 (2009) 888-898
28. Oki S., Chiba A., Yamamura T., and Miyake S. The clinical implication and molecular mechanism of preferential IL-4 production by modified glycolipid-stimulated NKT cells. J. Clin. Invest. 113 (2004) 1631-1640
29. Sidobre S., Hammond K.J.L., Benazet-Sidobre L., Maltsev S.D., Richardson S.K., Ndonye R.M., et al. The T cell antigen receptor expressed by Vα14i NKT cells has a unique mode of glycosphingolipid antigen recognition. Proc. Natl. Acad. Sci. USA 101 (2004) 12254-12259
30. Kabsch W. Automatic processing of rotation diffraction data from crystals of initially unknown symmetry and cell constants. J. Appl. Crystallogr. 26 (1993) 795-800
31. Read R.J. Pushing the boundaries of molecular replacement with maximum likelihood. Acta Crystallogr., Sect. D: Biol. Crystallogr. 57 (2001) 1373-1382
32. Emsley P., and Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr., Sect. D: Biol. Crystallogr. 60 (2004) 2126-2132
33. Murshudov G.N., Vagin A.A., and Dodson E.J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr., Sect. D: Biol. Crystallogr. 53 (1997) 240-255
34. Sheriff S., Hendrickson W.A., and Smith J.L. Structure of myohemerythrin in the azidomet state at 1.7/1.3 Å resolution. J. Mol. Biol. 197 (1987) 273-296
35. Kabsch W. A solution for the best rotation to relate two sets of vectors. Acta Crystallogr. A32 (1976) 922-923
36. Martin, A. C. R. & Porter, C. T. http://www.bioinf.org.uk/software/profit.